---
title: "Long-term fatigue after radiotherapy in non-metastatic prostate cancer: five-year REQUITE QLQ-C30"
id: "british-journal-of-cancer-0-long-term-fatigue-based-on-the-eortc-qlq-c30-up-to-five-years-after"
canonical_url: "https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-long-term-fatigue-based-on-the-eortc-qlq-c30-up-to-five-years-after"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "British Journal of Cancer"
source_url: "https://www.nature.com/articles/s41416-026-03644-2"
published_at: "2026-11-04T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Long-term fatigue after radiotherapy in non-metastatic prostate cancer: five-year REQUITE QLQ-C30
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-long-term-fatigue-based-on-the-eortc-qlq-c30-up-to-five-years-after
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** British Journal of Cancer
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41416-026-03644-2)
- **Published At:** 2026-11-04T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators analysed 1,758 men with non-metastatic **prostate cancer** treated with radiotherapy between 2014 and 2016 who completed the **EORTC QLQ-C30** up to five years after treatment. - About 35% of patients (608/1758) reported clinically important **fatigue** at least once during the observation window; point prevalence at two years was 14%. - Logistic regression linked fatigue two years after radiotherapy to higher pre-radiotherapy fatigue (OR 8.67), self-reported diabetes (OR 1.94), body mass index (OR 1.07 per unit), and older age (OR 1.03 per year). - Long-term fatigue correlated with co-occurring symptoms: pain, insomnia, pelvic symptoms, impaired function, and reduced overall quality of life. - Latent class growth analysis identified four distinct fatigue trajectories: low (45%), moderate (42%), elevated-but-decreasing (8%), and increasing (6%) mean fatigue levels across five years. - Diabetes increased the probability of being in the increasing trajectory by six percentage points, according to multinomial regression. - Authors reported that pre-treatment fatigue level and diabetes may help stratify patients for intensified follow-up and targeted aftercare programmes. - The study used prospectively collected patient-reported outcomes; specific radiotherapy dosing details and further methodological minutiae were not reported in the supplied abstract text.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41416-026-03644-2#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![British Journal of Cancer](https://media.springernature.com/full/nature-cms/uploads/product/bjc/header-76ac17391903a21e28f15ff5df31f5fa.svg) ](https://www.nature.com/bjc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41416-026-03644-2) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/bjc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/bjc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/bjc/news-and-comment) * [ Current issue ](https://www.nature.com/bjc/current-issue) * [ Collections ](https://www.nature.com/bjc/collections) * [Follow us on X ](https://twitter.com/BrJCancer) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Journal Information ](https://www.nature.com/bjc/journal-information) * [ Open access publishing ](https://www.nature.com/bjc/open-access) * [ Editors ](https://www.nature.com/bjc/editors) * [ Contact ](https://www.nature.com/bjc/contact) * [ Special Issues ](https://www.nature.com/bjc/special-issues) * [ For Advertisers ](https://www.nature.com/bjc/advertising) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors & Referees ](https://www.nature.com/bjc/authors-and-referees) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/bjc/open-access-funding) * [Submit manuscript ](https://mts-bjcancer.nature.com/) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) 1. [nature](https://www.nature.com/) 2. [british journal of cancer](https://www.nature.com/bjc) 3. [articles](https://www.nature.com/bjc/articles?type=article) 4. article Long-term fatigue based on the EORTC QLQ-C30 up to five years after radiotherapy and its trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study [ Download PDF ](https://www.nature.com/articles/s41416-026-03644-2.pdf) [ Download PDF ](https://www.nature.com/articles/s41416-026-03644-2.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 04 November 2026 Epidemiology # Long-term fatigue based on the EORTC QLQ-C30 up to five years after radiotherapy and its trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study * [Philipp Heumann](https://www.nature.com/articles/s41416-026-03644-2#auth-Philipp-Heumann-Aff1-Aff2) [ORCID: orcid.org/0000-0001-6650-6045](https://orcid.org/0000-0001-6650-6045)[1](https://www.nature.com/articles/s41416-026-03644-2#Aff1),[2](https://www.nature.com/articles/s41416-026-03644-2#Aff2), * [Juan C. Rosas](https://www.nature.com/articles/s41416-026-03644-2#auth-Juan_C_-Rosas-Aff1)[1](https://www.nature.com/articles/s41416-026-03644-2#Aff1), * [Miguel E. Aguado-Barrera](https://www.nature.com/articles/s41416-026-03644-2#auth-Miguel_E_-Aguado_Barrera-Aff3-Aff4) [ORCID: orcid.org/0000-0002-7822-6726](https://orcid.org/0000-0002-7822-6726)[3](https://www.nature.com/articles/s41416-026-03644-2#Aff3),[4](https://www.nature.com/articles/s41416-026-03644-2#Aff4), * [David Azria](https://www.nature.com/articles/s41416-026-03644-2#auth-David-Azria-Aff5)[5](https://www.nature.com/articles/s41416-026-03644-2#Aff5), * [Axel Benner](https://www.nature.com/articles/s41416-026-03644-2#auth-Axel-Benner-Aff6)[6](https://www.nature.com/articles/s41416-026-03644-2#Aff6), * [Erik Briers](https://www.nature.com/articles/s41416-026-03644-2#auth-Erik-Briers) [na2](https://www.nature.com/articles/s41416-026-03644-2#na2), * [Renée Bultijnck](https://www.nature.com/articles/s41416-026-03644-2#auth-Ren_e-Bultijnck-Aff7-Aff8) [ORCID: orcid.org/0000-0003-4122-2323](https://orcid.org/0000-0003-4122-2323)[7](https://www.nature.com/articles/s41416-026-03644-2#Aff7),[8](https://www.nature.com/articles/s41416-026-03644-2#Aff8), * [Ananya Choudhury](https://www.nature.com/articles/s41416-026-03644-2#auth-Ananya-Choudhury-Aff9)[9](https://www.nature.com/articles/s41416-026-03644-2#Aff9), * [Antonio Gómez-Caamaño](https://www.nature.com/articles/s41416-026-03644-2#auth-Antonio-G_mez_Caama_o-Aff4-Aff10) [ORCID: orcid.org/0000-0002-9773-4590](https://orcid.org/0000-0002-9773-4590)[4](https://www.nature.com/articles/s41416-026-03644-2#Aff4),[10](https://www.nature.com/articles/s41416-026-03644-2#Aff10), * [Rudolf Kaaks](https://www.nature.com/articles/s41416-026-03644-2#auth-Rudolf-Kaaks-Aff1) [ORCID: orcid.org/0000-0003-3751-3929](https://orcid.org/0000-0003-3751-3929)[1](https://www.nature.com/articles/s41416-026-03644-2#Aff1), * [Maarten Lambrecht](https://www.nature.com/articles/s41416-026-03644-2#auth-Maarten-Lambrecht-Aff11) [ORCID: orcid.org/0000-0002-8746-2691](https://orcid.org/0000-0002-8746-2691)[11](https://www.nature.com/articles/s41416-026-03644-2#Aff11), * [Tiziana Rancati](https://www.nature.com/articles/s41416-026-03644-2#auth-Tiziana-Rancati-Aff12) [ORCID: orcid.org/0000-0002-7849-603X](https://orcid.org/0000-0002-7849-603X)[12](https://www.nature.com/articles/s41416-026-03644-2#Aff12), * [Barry S. Rosenstein](https://www.nature.com/articles/s41416-026-03644-2#auth-Barry_S_-Rosenstein-Aff13)[13](https://www.nature.com/articles/s41416-026-03644-2#Aff13), * [Dirk De Ruysscher](https://www.nature.com/articles/s41416-026-03644-2#auth-Dirk-De_Ruysscher-Aff14)[14](https://www.nature.com/articles/s41416-026-03644-2#Aff14), * [Martina E. Schmidt](https://www.nature.com/articles/s41416-026-03644-2#auth-Martina_E_-Schmidt-Aff15) [ORCID: orcid.org/0000-0002-2095-2426](https://orcid.org/0000-0002-2095-2426)[15](https://www.nature.com/articles/s41416-026-03644-2#Aff15), * [Susanne Singer](https://www.nature.com/articles/s41416-026-03644-2#auth-Susanne-Singer-Aff16)[16](https://www.nature.com/articles/s41416-026-03644-2#Aff16), * [Elena Sperk](https://www.nature.com/articles/s41416-026-03644-2#auth-Elena-Sperk-Aff17) [ORCID: orcid.org/0000-0002-8771-8124](https://orcid.org/0000-0002-8771-8124)[17](https://www.nature.com/articles/s41416-026-03644-2#Aff17), * [Hilary Stobart](https://www.nature.com/articles/s41416-026-03644-2#auth-Hilary-Stobart) [na2](https://www.nature.com/articles/s41416-026-03644-2#na2), * [Ana Vega](https://www.nature.com/articles/s41416-026-03644-2#auth-Ana-Vega-Aff3-Aff4-Aff18) [ORCID: orcid.org/0000-0002-7416-5137](https://orcid.org/0000-0002-7416-5137)[3](https://www.nature.com/articles/s41416-026-03644-2#Aff3),[4](https://www.nature.com/articles/s41416-026-03644-2#Aff4),[18](https://www.nature.com/articles/s41416-026-03644-2#Aff18), * [Liv Veldeman](https://www.nature.com/articles/s41416-026-03644-2#auth-Liv-Veldeman-Aff7-Aff8)[7](https://www.nature.com/articles/s41416-026-03644-2#Aff7),[8](https://www.nature.com/articles/s41416-026-03644-2#Aff8), * [Tim Ward](https://www.nature.com/articles/s41416-026-03644-2#auth-Tim-Ward) [na2](https://www.nature.com/articles/s41416-026-03644-2#na2), * [Adam Webb](https://www.nature.com/articles/s41416-026-03644-2#auth-Adam-Webb-Aff19) [ORCID: orcid.org/0000-0002-6699-0479](https://orcid.org/0000-0002-6699-0479)[19](https://www.nature.com/articles/s41416-026-03644-2#Aff19), * [Catharine M. West](https://www.nature.com/articles/s41416-026-03644-2#auth-Catharine_M_-West-Aff20) [ORCID: orcid.org/0000-0002-0839-3449](https://orcid.org/0000-0002-0839-3449)[20](https://www.nature.com/articles/s41416-026-03644-2#Aff20), * [Jenny Chang-Claude](https://www.nature.com/articles/s41416-026-03644-2#auth-Jenny-Chang_Claude-Aff1)[1](https://www.nature.com/articles/s41416-026-03644-2#Aff1), * [Christopher J. Talbot](https://www.nature.com/articles/s41416-026-03644-2#auth-Christopher_J_-Talbot-Aff19) [ORCID: orcid.org/0000-0001-7406-8962](https://orcid.org/0000-0001-7406-8962)[19](https://www.nature.com/articles/s41416-026-03644-2#Aff19), * [Tim Rattay](https://www.nature.com/articles/s41416-026-03644-2#auth-Tim-Rattay-Aff19)[19](https://www.nature.com/articles/s41416-026-03644-2#Aff19), * [REQUITE/REQUITEplus/RADprecise consortia](https://www.nature.com/articles/s41416-026-03644-2#group-1) & * … * [Petra Seibold](https://www.nature.com/articles/s41416-026-03644-2#auth-Petra-Seibold-Aff1-Aff21) [ORCID: orcid.org/0000-0001-7360-6335](https://orcid.org/0000-0001-7360-6335)[1](https://www.nature.com/articles/s41416-026-03644-2#Aff1),[21](https://www.nature.com/articles/s41416-026-03644-2#Aff21) Show authors [_British Journal of Cancer_](https://www.nature.com/bjc) (2026) [Cite this article](https://www.nature.com/articles/s41416-026-03644-2#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract ### Background Fatigue is a common symptom in cancer patients associated with impaired quality of life (QoL). Little is known about long-term fatigue trajectories in prostate cancer (PCa) patients. ### Methods Using the European Organisation for Research and Treatment of Cancer Quality of Life Group Core Questionnaire (EORTC QLQ-C30), 1758 men treated with radiotherapy (2014–2016) for non-metastatic PCa prospectively reported fatigue up to five years later. Associations between pre-radiotherapy characteristics and clinically important fatigue (Score: ≥39/100) two years post-radiotherapy were investigated using logistic regression. Fatigue trajectories were explored using latent class growth analysis and multinomial regression. ### Results About 35% (608/1758) of patients experienced clinically important fatigue at least once from the start of radiotherapy up to five years later. Two years post-radiotherapy, 14% of patients reported fatigue, which was associated with pre-radiotherapy fatigue level (OR: 8.67), self-reported diabetes (OR: 1.94), BMI (OR: 1.07), and age (OR: 1.03). Long-term fatigue was strongly linked to pain, insomnia, pelvic symptoms, functional impairments, and reduced QoL. Four fatigue trajectories were identified, characterised by low (45%), moderate (42%), elevated and decreasing (8%), and (6%) increasing mean fatigue levels. Diabetes was associated with a 6 percentage point increase in the probability of experiencing an increasing fatigue trajectory. ### Conclusions The findings emphasise the need for early identification of PCa patients susceptible to long-term fatigue. PCa patients with elevated pre-radiotherapy fatigue levels and diabetes may require closer monitoring in risk-stratified aftercare programmes. ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer epidemiology](https://www.nature.com/subjects/cancer-epidemiology) * [Prostate cancer](https://www.nature.com/subjects/prostate-cancer) ## Background Prostate cancer is the second most commonly diagnosed cancer and fifth leading cause of cancer death in men [[1](https://www.nature.com/articles/s41416-026-03644-2#ref-CR1 "Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834 .")]. Fatigue is a common and highly distressing symptom in cancer patients and survivors, defined as ‘a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning’ [[2](https://www.nature.com/articles/s41416-026-03644-2#ref-CR2 "Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11:597–609. https://doi.org/10.1038/nrclinonc.2014.127 ."), [3](https://www.nature.com/articles/s41416-026-03644-2#ref-CR3 "NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue Version 2.2025. https://www.nccn.org/ . Accessed April 8, 2025.")]. Up to 82% of men with prostate cancer experience fatigue during and/or after treatment associated with functional impairment and poorer quality of life (QoL) [[4](https://www.nature.com/articles/s41416-026-03644-2#ref-CR4 "Cornford P, Robijn E, Rogers E, Wassersug R, Fleure L. Fatigue in Prostate Cancer: A Roundtable Discussion and Thematic Literature Review. Eur Urol Open Sci. 2024;63:119–25. https://doi.org/10.1016/j.euros.2024.03.003 ."), [5](https://www.nature.com/articles/s41416-026-03644-2#ref-CR5 "Charalambous A, Giannakopoulou M, Bozas E, Paikousis L. Parallel and serial mediation analysis between pain, anxiety, depression, fatigue and nausea, vomiting and retching within a randomised controlled trial in patients with breast and prostate cancer. BMJ Open. 2019;9:e026809 https://doi.org/10.1136/bmjopen-2018-026809 .")]. The aetiology of fatigue remains poorly understood, with several biological mechanisms hypothesised, including dysregulation of cytokines and the hypothalamic-pituitary-adrenal axis [[2](https://www.nature.com/articles/s41416-026-03644-2#ref-CR2 "Bower JE. Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11:597–609. https://doi.org/10.1038/nrclinonc.2014.127 .")]. Although frequently occurring during radiation and/or androgen deprivation therapy (ADT), a substantial proportion of prostate cancer patients and survivors report being fatigued even years after completing treatment [[6](https://www.nature.com/articles/s41416-026-03644-2#ref-CR6 "Dickinson K, Kupzyk K, Saligan L. Evaluating dimensions of fatigue in men with prostate cancer receiving radiation therapy. Cancer Nurs. 2021;44:71–78. https://doi.org/10.1097/NCC.0000000000000782 ."), [7](https://www.nature.com/articles/s41416-026-03644-2#ref-CR7 "Thong MSY, van Noorden CJF, Steindorf K, Arndt V. Cancer-related fatigue: causes and current treatment options. Curr Treat Options Oncol. 2020;21:17 https://doi.org/10.1007/s11864-020-0707-5 .")]. Previous findings in prostate and other cancer populations suggest that fatigue patterns vary over time between patients, with some experiencing a severe course of fatigue years later [[8](https://www.nature.com/articles/s41416-026-03644-2#ref-CR8 "Scott JA, Lasch KE, Barsevick AM, Piault-Louis E. Patients’ experiences with cancer-related fatigue: a review and synthesis of qualitative research. Oncol Nurs Forum. 2011;38:E191–203. https://doi.org/10.1188/11.ONF.E191-E203 ."),[9](https://www.nature.com/articles/s41416-026-03644-2#ref-CR9 "Feng L, Chen MK, Lukkahatai N, Hsiao CP, Kaushal A, Sechrest L, et al. Clinical Predictors of Fatigue in Men With Non-Metastatic Prostate Cancer Receiving External Beam Radiation Therapy. Clin J Oncol Nurs. 2015;19:744–50. https://doi.org/10.1188/15.CJON.744-750 ."),[10](https://www.nature.com/articles/s41416-026-03644-2#ref-CR10 "Gavin AT, Drummond FJ, Donnelly C, O’Leary E, Sharp L, Kinnear HR. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int. 2015;116:397–406. https://doi.org/10.1111/bju.13036 ."),[11](https://www.nature.com/articles/s41416-026-03644-2#ref-CR11 "Feng LR, Fuss T, Dickinson K, Ross A, Saligan LN. Co-occurring symptoms contribute to persistent fatigue in prostate cancer. Oncology. 2019;96:183–91. https://doi.org/10.1159/000494620 ."),[12](https://www.nature.com/articles/s41416-026-03644-2#ref-CR12 "Stone P, Hardy J, Huddart R, A’Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36:1134–41. https://doi.org/10.1016/s0959-8049\(00\)00084-8 ."),[13](https://www.nature.com/articles/s41416-026-03644-2#ref-CR13 "Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fosså SD. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate. 2010;70:1480–9. https://doi.org/10.1002/pros.21183 ."),[14](https://www.nature.com/articles/s41416-026-03644-2#ref-CR14 "Maliski SL, Kwan L, Orecklin JR, Saigal CS, Litwin MS. Predictors of fatigue after treatment for prostate cancer. Urology. 2005;65:101–8. https://doi.org/10.1016/j.urology.2004.08.031 ."),[15](https://www.nature.com/articles/s41416-026-03644-2#ref-CR15 "Lilleby W, Stensvold A, Dahl AA. Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer. Acta Oncol. 2016;55:807–13. https://doi.org/10.3109/0284186X.2015.1127417 ."),[16](https://www.nature.com/articles/s41416-026-03644-2#ref-CR16 "Joseph N, Cicchetti A, McWilliam A, Webb A, Seibold P, Fiorino C, et al. High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer. Front Oncol. 2022;12:937934. https://doi.org/10.3389/fonc.2022.937934 ."),[17](https://www
## Related Clinical Research

- [Long-term fatigue dimensions after radiotherapy in non-metastatic prostate cancer: MFI trajectorie](https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-long-term-fatigue-dimensions-in-the-multidimensional-fatigue-inventory-mfi-up.md)
- [Limits of Postpartum Psychiatry Revealed by the Lindsay Clancy Case](https://medichelpline.com/clinical-feed/stat-news-1-opinion-the-lindsay-clancy-case-shows-the-limits-of-postpartum-psychiatry.md)
- [Definium Therapeutics reports Phase 3 LSD pill DT120 reduced anxiety in generalized anxiety disord](https://medichelpline.com/clinical-feed/stat-news-1-stat-definium-therapeutics-says-its-lsd-therapy-eased-anxiety-in-late-stage.md)
- [Replacing animal fats with plant fats linked to lower mortality after nonmetastatic prostate cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-swapping-animal-fats-with-plant-fats-may-lower-risk-of-death-after-prostate.md)
- [Pain prevalence and outcomes in polyendocrine metabolic ovarian syndrome (PMOS): EHR-based analysis](https://medichelpline.com/clinical-feed/pubmed-42663451.md) (DOI: 10.7554/eLife.103875)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.